论文部分内容阅读
目的 观察斯奇康注射液的免疫治疗效果 ,缩短结核性胸膜炎胸水吸收时间及减少胸膜增厚后遗症。方法 随机抽样分为斯奇康治疗组和对照组 ,在全身化疗的基础上 ,斯奇康注射液胸膜腔注入。结果 近期疗效有差异 ,胸水吸收治愈率 ,治疗组为 84 .3% ,对照组为 5 0 .0 % ;胸水 10d以内吸收者 ,治疗组与对照组分别为 4 3.7%和 12 .5 % ;胸膜增厚 ,治疗组 15 .6 % ,对照组为 5 0 .0 %。结论 斯奇康注射液胸膜腔内注入对结核性胸膜炎治疗有较大临床应用价值
Objective To observe the effect of immunotherapy of schizophrenic injection, shorten the time of pleural effusion of pleural effusion and reduce the sequelae of pleural thickening. Methods A random sample was divided into two groups: treatment group and control group. On the basis of systemic chemotherapy, STK injection was injected into pleural cavity. Results The curative effect was different in recent years. The cure rate of pleural effusion was 84.3% in the treatment group and 50.0% in the control group. The absorption rate in the pleural effusion within 10 days was 43.7% and 12.5% in the treatment group and the control group respectively. Pleural thickening, the treatment group 15.6%, the control group was 50.0%. Conclusion Intracranial injection of schicken injection has great clinical value in the treatment of tuberculous pleurisy